Stedman T J, Whiteford H A, Eyles D, Welham J L, Pond S M
Clinical Studies Unit, Wolston Park Hospital, Wacol, Australia.
J Clin Psychopharmacol. 1991 Feb;11(1):43-7.
In an open label study, two fixed doses of nifedipine (30 mg and 60 mg daily) were added to the usual antipsychotic drug treatments of 10 patients suffering from chronic schizophrenia. While no patient experienced significant improvements, statistically significant falls in Brief Psychiatric Rating Scales scores were observed. A significant reduction in Abnormal Involuntary Movement Scale scores was observed in those patients with tardive dyskinesia. After the addition of nifedipine, four of the 10 patients showed large increases in plasma neuroleptic activity (radioreceptor assay) that decreased to baseline levels within two weeks. The possibility that this represents competitive inhibition and subsequent induction of the liver metabolism of the antipsychotic drugs is discussed. Adverse effects encountered are also discussed.
在一项开放标签研究中，将两种固定剂量的硝苯地平（每日30毫克和60毫克）添加到10名慢性精神分裂症患者的常规抗精神病药物治疗中。虽然没有患者经历显著改善，但观察到简明精神病评定量表得分有统计学意义的下降。在患有迟发性运动障碍的患者中观察到异常不自主运动量表得分显著降低。添加硝苯地平后，10名患者中有4名血浆抗精神病药物活性大幅增加（放射受体测定法），并在两周内降至基线水平。讨论了这是否代表竞争性抑制以及随后抗精神病药物肝脏代谢的诱导。还讨论了所遇到的不良反应。
